Insulin glulisine

From WikiProjectMed
Jump to navigation Jump to search
Insulin glulisine
PDB: 6gv0​
Names
Trade namesApidra, Apidra SoloStar
Clinical data
Drug classInsulin (rapid acting)[1]
Main usesType 1 and type 2 diabetes[1]
Side effectsLow blood sugar, pain at the site of injection[2][1]
Pregnancy
category
  • AU: B3[3]
  • US: C (Risk not ruled out)[3]
Routes of
use		Subcutaneous, intravenous
External links
AHFS/Drugs.comMonograph
MedlinePlusa607033
Legal
License data
Legal status
Chemical and physical data
FormulaC258H384N64O78S6
Molar mass5822.64 g·mol−1

Insulin glulisine, sold under the brand name Apidra, is a rapid acting insulin used to treat type 1 and type 2 diabetes.[1] It is given by injection under the skin between 15 minutes before to 20 minutes after starting a meal.[1] It may also be used by injection into a vein.[4] It is generally used with a long acting insulin.[1]

Common side effects include low blood sugar and pain at the site of injection.[2][1] Other side effects may include allergic reactions, low potassium, and lipodystrophy.[1] It is made by recombinant DNA techniques.[2]

Insulin glulisine was approved for medical use in the United States and Europe in 2004.[1][2] In the United Kingdom 300 units costs the NHS about £6 as of 2021.[5] In the United States this amount costs just over 100 USD.[6]

Medical uses

Insulin glulisine is indicated for the treatment of diabetes mellitus.[2][4]

Dosage

The typical dose of all insulins in type 1 DM is 0.2 to 1 unit/kg per day.[1]

Chemistry

It differs from human insulin in that the amino acid asparagine at position B3 is replaced by lysine and the lysine in position B29 is replaced by glutamic acid.[7]

History

It was developed by Sanofi-Aventis.[8]

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 1.9 "Insulin Glulisine Monograph for Professionals". Drugs.com. Archived from the original on 8 August 2020. Retrieved 26 November 2021.
  2. ↑ 2.0 2.1 2.2 2.3 2.4 2.5 "Apidra EPAR". European Medicines Agency (EMA). Archived from the original on 10 October 2020. Retrieved 7 October 2020.
  3. ↑ 3.0 3.1 "Insulin glulisine Use During Pregnancy". Drugs.com. 6 April 2020. Archived from the original on 4 December 2020. Retrieved 21 September 2020.
  4. ↑ 4.0 4.1 4.2 "Apidra- insulin glulisine injection, solution Apidra SoloStar- insulin glulisine injection, solution". DailyMed. 6 December 2019. Archived from the original on 25 March 2021. Retrieved 21 September 2020.
  5. ↑ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 754. ISBN 978-0857114105.
  6. ↑ "Apidra Prices, Coupons & Savings Tips". GoodRx. Archived from the original on 11 December 2021. Retrieved 26 November 2021.
  7. ↑ "Apidra (insulin glulisine) injection, solution". DailyMed. Archived from the original on 2010-06-15. Retrieved 2020-12-02.
  8. ↑ Jasek W, ed. (2007). Austria-Codex (in Deutsch) (2007/2008 ed.). Vienna: Österreichischer Apothekerverlag. ISBN 978-3-85200-181-4.

External links

Identifiers:
  • "Insulin glulisine". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on 2020-10-24. Retrieved 2020-12-02.
Stub icon

This drug article relating to the gastrointestinal system is a stub. You can help MDWiki by expanding it.

Retrieved from "https://mdwiki.org/w/index.php?title=Insulin_glulisine&oldid=1378839"